The clinical status and targets of 23 approved and 136 clinical trial multi-target anticancer drugs, focusing on co-targeting ALK, EGFR, HER2, Abl, VEGFR2, mTOR, PI3K, MEK, KIT, and DNA topoisomerase, demonstrated that the majority of approved (73.9%) and phase 3 (75.0%) drugs, as well as a significant portion of phase 2 (62.8%) and phase 1 (53.6%) drugs, co-targeted cancer drug escape pathways, suggesting a potential clinical advantage in co-targeting anticancer targets and drug escape pathways, encouraging further exploration of this strategy [166]. Here, KIT is linked to cancer.